COMMUNIQUÉS West-GlobeNewswire
-
Reunion Neuroscience to Participate in Upcoming Investor Conferences
19/02/2026 -
BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.
19/02/2026 -
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
19/02/2026 -
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
19/02/2026 -
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
19/02/2026 -
Kane Biotech Expands Commercial Activities in the United States
19/02/2026 -
Step Pharma secures €2.5 million EIC grant to accelerate development of dencatistat for CTPS2 null gynaecological tumours
19/02/2026 -
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million
19/02/2026 -
Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026
19/02/2026 -
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
19/02/2026 -
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
19/02/2026 -
Q-Sera announces the first launch of blood collection tubes using its patented Rapclot technology in Japan, opening opportunities for additional global partnerships
19/02/2026 -
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
19/02/2026 -
Ipsen S.A. publie ses comptes consolidés 2025
19/02/2026 -
Philips publishes its Annual Report 2025
19/02/2026 -
Reacta Healthcare Appoints Richard Nagle as Chair of Board of Directors
19/02/2026 -
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
19/02/2026 -
BioVersys and Partners’ Phase 2a Tuberculosis Trial Results Published in New England Journal of Medicine
19/02/2026 -
IBA and Shreeji sign multi‑site agreement for four cyclotrons to expand PET radiopharmaceutical manufacturing across India
19/02/2026
Pages